Y-tract infection (Urethritis caused by Mycoplasma genitalium) - Symptoms, Causes, Treatment & Prevention

📅 Updated: June 2026 ⏱️ 6 min read ✅ Medically reviewed
```html Y‑tract Infection (Urethritis caused by Mycoplasma genitalium)

Y‑tract Infection (Urethritis caused by Mycoplasma genitalium)

Overview

Urethritis refers to inflammation of the urethra, the tube that carries urine (and in males, semen) out of the body. When the inflammation is caused by the bacterium Mycoplasma genitalium (often abbreviated M. genitalium), the condition is commonly called a “Y‑tract infection.”

  • Who it affects: Both men and women can acquire the infection, but it is most frequently diagnosed in sexually active adults aged 15‑35 years.
  • Prevalence: In high‑income countries, M. genitalium is detected in 1‑3 % of the general population and in 10‑30 % of patients presenting with urethritis or cervicitis. 1 In the United States, the CDC estimates roughly 2 % of sexually active young adults carry the organism, making it the second most common cause of non‑gonococcal urethritis after Chlamydia trachomatis. 2

The organism is a very small, wall‑less bacterium that can attach to the epithelial cells of the urethra (and cervix, rectum, or throat), leading to chronic inflammation and, if untreated, complications such as pelvic inflammatory disease (PID) in women or epididymitis in men.

Symptoms

Symptoms can range from none (asymptomatic) to severe. They usually appear 1‑3 weeks after exposure, but some people develop symptoms months later.

  • Painful urination (dysuria): A burning sensation during or after voiding.
  • Urethral discharge:
    • Men: thin, watery or mucopurulent discharge from the penis.
    • Women: may notice increased vaginal discharge or a feeling of “wetness” in the vaginal area.
  • Urethral itching or irritation: A pruritic or gritty feeling.
  • Frequent urge to urinate: Even when the bladder is not full.
  • Painful ejaculation (in men): Discomfort after orgasm.
  • Pain in the lower abdomen or pelvic region: More common in women.
  • Rectal symptoms (if infected via anal sex): Discomfort, discharge, or bleeding.
  • Systemic signs (rare): Low‑grade fever or malaise, usually indicating spread to other sites.

Causes and Risk Factors

What causes the infection?

M. genitalium is transmitted primarily through sexual contact—vaginal, anal, or oral sex—with an infected partner. The bacterium lacks a cell wall, making it intrinsically resistant to many common antibiotics such as penicillins and cephalosporins.

Risk factors

  • Having more than one sexual partner or a new partner within the past 6 months.
  • Inconsistent or incorrect condom use.
  • Previous infection with another sexually transmitted infection (STI), especially chlamydia or gonorrhea.
  • Engaging in anal or oral sex without barrier protection.
  • Men who have sex with men (MSM); prevalence rates can be higher (up to 10 % in some studies). 3
  • Women with a history of PID, infertility work‑ups, or recurrent cervicitis.

Diagnosis

Because symptoms overlap with other STIs, laboratory confirmation is essential.

Step‑by‑step diagnostic approach

  1. Clinical assessment: Provider records symptoms, sexual history, and possible exposure.
  2. Sample collection:
    • Men: First‑void urine (FVU) or a urethral swab.
    • Women: Endocervical swab, vaginal swab, or FVU.
    • Rectal infection: Rectal swab (especially in MSM).
  3. NAAT (Nucleic Acid Amplification Test): The preferred method; it detects bacterial DNA/RNA with >90 % sensitivity and specificity. FDA‑cleared NAAT kits for M. genitalium are now available in many countries. 4
  4. Antimicrobial resistance testing (optional but increasingly recommended): Certain NAAT platforms can identify mutations linked to macrolide resistance (e.g., 23S rRNA gene). This guides therapy because up to 50 % of isolates in the U.S. carry macrolide‑resistance mutations. 5
  5. Exclusion of other STIs: Standard panels for chlamydia, gonorrhea, trichomoniasis, and HIV are usually done simultaneously.

Treatment Options

Effective treatment is more complex than for many other STIs due to rising antimicrobial resistance.

First‑line therapy (macrolide‑sensitive strains)

  • Azithromycin 1 g orally single dose OR 500 mg on day 1 followed by 250 mg daily for 4 days** (extended regimen). The extended regimen reduces resistance selection. 6

Alternative regimens (macrolide‑resistant or treatment failure)

  • Moxifloxacin 400 mg orally once daily for 7‑10 days (fluoroquinolone). Effective in >90 % of resistant cases, but requires caution in patients with QT prolongation or tendon disorders. 7
  • Newer agents under investigation (e.g., pristinamycin, lefamulin) may be options in the future.

Guideline‑driven algorithm (CDC 2021)

  1. Check local resistance data or perform resistance‑testing NAAT.
  2. If macrolide‑susceptible → give azithromycin (extended).
  3. If macrolide‑resistant or no testing → start moxifloxacin.
  4. Retest 3 weeks after therapy completion to confirm microbiologic cure.

Adjunctive measures

  • Partner notification and empiric treatment of sexual partners within 60 days of exposure.
  • Abstinence from sexual activity until both patient and partner have completed therapy and symptoms have resolved.
  • Pain relief: NSAIDs (ibuprofen 400 mg every 6 h) or acetaminophen as needed.

Living with Y‑tract infection (Urethritis caused by Mycoplasma genitalium)

Even after successful treatment, many people wonder how to manage daily life while the infection clears.

  • Hydration: Drink plenty of water (≥2 L/day) to dilute urine and reduce irritation.
  • Urination hygiene: Urinate after intercourse to flush out bacteria.
  • Warm sitz baths: 10‑15 minutes, twice daily, can soothe urethral discomfort.
  • Avoid irritants: Steer clear of perfumed soaps, douches, or spermicidal lubricants until symptoms subside.
  • Condom use: Continue consistent condom use for at least 7 days after finishing antibiotics (or as advised by your clinician).
  • Follow‑up testing: A repeat NAAT 3‑4 weeks after treatment helps ensure eradication, especially after macrolide‑resistant infection.
  • Emotional health: STI diagnoses can cause anxiety. Access counseling services, support groups, or trusted friends.

Prevention

  1. Consistent condom use: Male latex condoms reduce transmission by ~70 %; for anal sex, use extra‑strong or double condoms.
  2. Limit number of sexual partners: Fewer partners lower exposure risk.
  3. Regular STI screening: At least annually for sexually active adults; more frequent (every 3‑6 months) for high‑risk groups (e.g., MSM, sex workers).
  4. Prompt partner treatment: Treat all recent partners, even if asymptomatic, to prevent reinfection.
  5. Vaccination: No vaccine exists for M. genitalium, but staying up‑to‑date on HPV and Hepatitis B vaccines protects against other STI‑related complications.
  6. Open communication: Discuss STI testing and results with partners before sexual activity.

Complications

If left untreated, M. genitalium can cause several serious sequelae.

  • Pelvic inflammatory disease (PID): In women, infection can ascend to the uterus, fallopian tubes, and ovaries, leading to chronic pelvic pain, infertility, or ectopic pregnancy. Risk of PID after M. genitalium infection is estimated at 10‑15 % in untreated women. 8
  • Epididymitis: In men, inflammation of the epididymis may cause testicular pain and potential infertility.
  • Proctitis: Rectal infection can cause pain, bleeding, and discharge, especially in MSM.
  • Recurrent urethritis: Inadequately treated infection often recurs, leading to chronic discomfort.
  • Increased susceptibility to HIV: Inflammation of mucosal surfaces can facilitate HIV acquisition and transmission.

When to Seek Emergency Care

Go to an emergency department or call 911 if you experience any of the following:
  • Severe, sudden onset of abdominal or pelvic pain with fever (>38.5 °C / 101.3 °F).
  • Swelling, redness, or extreme tenderness of the scrotum (possible testicular torsion or severe epididymitis).
  • Vomiting, confusion, or dizziness alongside urinary symptoms (signs of sepsis).
  • Blood in the urine or urethral discharge that is dark, foul‑smelling, or accompanied by high fever.
  • Rapid heart rate (>120 bpm) or low blood pressure (systolic <90 mm Hg).

These symptoms require immediate medical attention to prevent life‑threatening complications.

References

  1. World Health Organization. “Global prevalence of Mycoplasma genitalium: systematic review and meta‑analysis.” *WHO* 2021.
  2. Centers for Disease Control and Prevention. “Sexually Transmitted Infections – Mycoplasma genitalium.” Updated 2023. https://www.cdc.gov/std/mgenitalium/default.htm
  3. J. F. Manhart et al., “Prevalence of Mycoplasma genitalium among men who have sex with men in the United States,” *Clinical Infectious Diseases*, vol. 71, no. 5, 2020.
  4. European Centre for Disease Prevention and Control. “Guidelines for the diagnosis of Mycoplasma genitalium infection.” 2022.
  5. J. J. Unemo & B. M. Jensen, “Antimicrobial resistance in Mycoplasma genitalium – systematic review,” *Lancet Infectious Diseases*, 2022.
  6. CDC. “Sexually Transmitted Diseases Treatment Guidelines, 2021.” https://www.cdc.gov/std/treatment-guidelines.htm
  7. H. L. Workowski et al., “Fluoroquinolone treatment of macrolide‑resistant Mycoplasma genitalium,” *New England Journal of Medicine*, 2021.
  8. National Institutes of Health. “Pelvic inflammatory disease (PID) and infertility.” NIH MedlinePlus, 2023.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References